Exploratory Observational Prospective Study in Neonatal and Pediatric Congenital Diaphragmatic Hernia

Congenital Diaphragmatic Hernia Clinical Trial

Official title:

ECHO-CDH - Exploratory Observational Prospective Study in Neonatal and Pediatric Congenital Diaphragmatic Hernia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04114578
• Other study ID #: 2020-4892
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: July 30, 2024

Study information

• Verified date: March 2024
• Source: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CDH is associated with lung hypoplasia, pulmonary hypertension, and left ventricular hypoplasia.

Use of new STE techniques (heart ultrasound) showed that CDH newborns have decreased LV size and function, potentially explaining the non-response to iNO, and that these cardiac findings were associated with poor outcomes. Our hypothesis: CDH newborns persist to have some degree of LV hypoplasia in the pediatric and adolescent life and pulmonary pressures remain increased during growth. Patients with decreased cardiac performance by STE and/or with PH have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile

Description:

The principal investigator hypothesize that CDH newborns have disturbed cardiac performance and increased pulmonary pressures during neonatal life and at different pediatric ages. The principal investigator also postulate that those with decreased cardiac performance by STE and/or with PH have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile, that CDH patients have some remaining degree of LV hypoplasia at pediatric/adolescent age and that novel echocardiography techniques will detect anomalies not uncovered by conventional imaging.

This study is a prospective study. Cohorts will be simultaneously recruited at different neonatal and pediatric ages to create various age groups of the CDH populations.

Groups will be synchronized with the current follow-up programs to ease feasibility.

Patient Population will be CDH patients admitted to the NICU at the MCH or followed in the clinic. Patients will be recruited during hospitalization or at the different age groups corresponding to their regular CDH follow-up.

Echocardiography will be targeted to acquire: RV and LV function by STE, 3D derived RV/LV volumes and performance , conventional systolic/diastolic RV and LV function parameters (such as: ejection fraction by Simpson's Biplane, tricuspid annular plane systolic excursion and tissue Doppler velocities), cardiac outputs and pulmonary pressure estimates. For patient's safety, responsible clinician will be alerted when a clinically significant anomaly is detected on the research echocardiography. Same echocardiography protocol will be applied to controls.

Associated to echocardiography data, The principal investigator will complete a chart review to extract important neonatal/pediatric demographic and clinical data. Variables extracted, among others, will include perinatal details (mode of delivery, maternal conditions, APGAR scores), sex, birth weight, clinical course and major morbidities. Bayley Scales of Infant and Toddler Development - Third Edition, a standardized evaluation for motor, cognitive and language abilities, is done on all patients with CDH at 18 months PMA at the MCH. When available for age groups beyond 18 months of age, these scores will be recorded. As well, assessment tools describing functional and developmental status will be filled with parents (or legal guardian) and/or pre-adolescents/adolescents. These tools will be the: Ages & Stages Questionnaires 3 (a parent report of developmental skills for ages of 2 to 60 months , the Clinical Adaptive Test /Clinical Linguistic Auditory Milestone Scale (CAT/CLAMS), which has a high correlation with the Bayley Scales of Infant Development and is a neurodevelopmental assessment tool of infants and toddlers) and the Pediatric Quality of Life Inventory Survey (a pre-adolescent and adolescent report on quality of life and functional status).

Patients with CDH will be compared to controls (1:1) recruited contemporaneously. Clinics targeted for control groups include the dermatology, orthopedic, trauma follow-up and neurology clinic for benign seizures episodes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: July 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion:

• CDH patients admitted to the MCH-NICU

• CDH followed at the MCH CDH clinic

Exclusion:

• Prematurity (< 36 weeks)

• Diagnosis at > 7 days of life

• Bilateral CDH

• Congenital cardiac defect (excluding a patent ductus arteriosus (PDA), atrial septal defect (ASD) or ventricular septal defect (VSD)) and/or other major anomaly/genetic syndrome.

Related Conditions & MeSH terms

• Congenital Diaphragmatic Hernia
• Hernia
• Hernia, Diaphragmatic
• Hernias, Diaphragmatic, Congenital

Intervention

Other:
• Echocardiography
Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.

Locations

Country	Name	City	State
Canada	Mcgill University Health Centre	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain)by %	Within 24 hours of life
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain)by %	Between day 3 to 5 of life
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain)by %	Between 2 to 3 weeks of life
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain)by %	age of 4 and/or 9 months
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain)by %	3, 5 and/or 8 years
Primary	Assessment of cardiac function	Our primary outcome is cardiac function assessed by STE using peak longitudinal strain) by %	11, 14 and/or 17 years
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	Within 24 hours of life
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	Between day 3 to 5 of life
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	Between 2 to 3 weeks of life
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	age of 4 and/or 9 months
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	3, 5 and/or 8 years
Secondary	Prevalence of pulmonary hypertension	CDH newborns with pulmonary hypertension have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile (by mm/Hg)	11, 14 and/or 17 years